Special Issue "Targeted Therapy of Hepatocellular Carcinoma: Present and Future"
Deadline for manuscript submissions: closed (20 August 2015)
Dr. Stephen L. Chan
Department of Clinical Oncology, Prince of Wales Hospital, Shatin, HKSAR, China
Interests: hepatocellular carcinoma; pancreatic cancer; biliary tract cancer; biomarker; inflammation; targeted therapy
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Drug development for HCC used to be slow due to the relative chemo-refractoriness of the tumor and underlying co-morbid cirrhosis in most patients. Since 2008, clinical trial results on sorafenib have led to development of molecular targeted agents for HCC. For the past 5 years, a number of tyrosine kinase inhibitors have completed phase III testing but all of them have turned out to be negative. These studies persistently reported a median overall survival of 9 to 10 months, indicating that the benefit of an existing panel of targeted agents may have reached a plateau for advanced HCC. To overcome this deadlock, novel agents and concepts are needed from researchers of the HCC research world.
This Special Issue provides an Open Access opportunity to publish research and review articles on targeted therapy for HCC. The focus will be put on a comprehensive review of the current literatures as well as insights into the improvement of success rate of clinical trials on novel agents for the aggressive tumor.
Dr. Stephen L. Chan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 350 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hepatocellular carcinoma
- clinical trial
- targeted agent
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: Radiological Assessment of Antiangiogenic Therapies for Hepatocellular Carcinoma: Which Criteria Apply?
Authors: Mohamed Bouattour 1,*, onorina Bruno 2 and Johanna Wassermann 3
Affiliations:1 Department of Hepatology. Hôpital Beaujon ; 100 Boulevard du Général Leclerc. 92110 Clichy, France
2 Department of Radiology. Hôpital Beaujon; 100 Boulevard du Général Leclerc. 92110 Clichy, France
3 Department of Medical Oncology. Hôpital Pitié-Salpêtrière; 47-83 boulevard de l'Hôpital
75013 Paris, France
Author to whom correspondence should be addressed; E-Mail: email@example.com; Tel.: +33 1 40 87 55 25; Fax: +33 1 47 39 61 78
Abstract: The sorafenib, an oral multi-tyrosine kinase inhibitor, is currently approved by regulatory agencies as the standard-of-care first-line treatment of advanced hepatocellular carcinoma (HCC). Sorafenib is the first and so far the sole drug that has shown overall survival benefit in patients with advanced HCC in two III trials. The remarkable results obtained by sorafenib are contrasting with objective response rate inferior to 5% according to RECIST criteria. Distinct to standard chemotherapies, low objective response rates were also observed with other antiangiogenic agents tested in HCC. Tumor shrinkage and dimensional changes, usually assessed to define response to cytotoxic drugs based on morphological RECIST criteria, were rarely observed in patients treated with antiangiogenic therapies. Hence, Radiological evaluation of efficacy using standard RECIST criteria is often inappropriate to assess response to targeted agents in HCC patients. Alternatives criteria of response, such as mRECIST, EASL and CHOI criteria have been proposed to assess the direct effect of antianagiogenic therapies in HCC. In this review, we purpose to analyze relevance of these new criteria in clinical practice and their performance to predict response of antiangiogenic therapies for HCC.